These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19940201)

  • 1. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine.
    Blackwell S
    Ann Clin Biochem; 2010 Jan; 47(Pt 1):17-28. PubMed ID: 19940201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADMA: its role in vascular disease.
    Cooke JP
    Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
    De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
    Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH; Bode-Böger SM
    Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R
    Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
    Vallance P; Leiper J
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1023-30. PubMed ID: 15105281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetric dimethylarginine and critical illness.
    Brinkmann SJ; de Boer MC; Buijs N; van Leeuwen PA
    Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):90-7. PubMed ID: 24281375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
    Weis M; Kledal TN; Lin KY; Panchal SN; Gao SZ; Valantine HA; Mocarski ES; Cooke JP
    Circulation; 2004 Feb; 109(4):500-5. PubMed ID: 14732750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine--an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction.
    McCarty MF
    Med Hypotheses; 2004; 63(4):699-708. PubMed ID: 15325021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric dimethylarginine: clinical applications in pediatric medicine.
    Tain YL; Huang LT
    J Formos Med Assoc; 2011 Feb; 110(2):70-7. PubMed ID: 21377060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADMA and hyperhomocysteinemia.
    Dayal S; Lentz SR
    Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
    Böger RH
    Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
    Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
    JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biology and therapeutic potential of the DDAH/ADMA pathway.
    Arrigoni F; Ahmetaj B; Leiper J
    Curr Pharm Des; 2010; 16(37):4089-102. PubMed ID: 21247398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of asymmetric dimethylarginine.
    Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
    Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression.
    Gates PE; Boucher ML; Silver AE; Monahan KD; Seals DR
    J Appl Physiol (1985); 2007 Jan; 102(1):63-71. PubMed ID: 16946027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric Dimethylarginine (ADMA): a promising biomarker for cardiovascular disease?
    Bouras G; Deftereos S; Tousoulis D; Giannopoulos G; Chatzis G; Tsounis D; Cleman MW; Stefanadis C
    Curr Top Med Chem; 2013; 13(2):180-200. PubMed ID: 23470077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance.
    Teerlink T
    Clin Chem Lab Med; 2005; 43(10):1130-8. PubMed ID: 16197310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.